Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
cardiovascular
diabetes
gliflozins
sodium-glucose co-transporter-2 inhibitors
type 2 diabetes mellitus
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
17
04
2019
revised:
16
06
2019
accepted:
26
06
2019
pubmed:
3
7
2019
medline:
29
9
2020
entrez:
3
7
2019
Statut:
ppublish
Résumé
Diabetes mellitus in Asia accounts for more than half of the global prevalence. There is a high prevalence of cardiovascular disease (CVD) in the region among people with type 2 diabetes mellitus (T2DM) and it is often associated with multiple risk factors including hypertension, renal disease and obesity. The early onset of T2DM and the eventual long disease duration portends an increasing proportion of the population to premature CVD. In addition to lowering blood glucose, sodium-glucose co-transporter-2 (SGLT-2) inhibitors exert favourable effects on multiple risk factors (including blood pressure, body weight and renal function) and provide an opportunity to reduce the risk of CVD in patients with T2DM. In this article, we consolidated the existing literature on SGLT-2 inhibitor use in Asian patients with T2DM and established contemporary guidance for clinicians. We extensively reviewed recommendations from international and regional guidelines, published data from clinical trials in the Asian population (dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, luseogliflozin and tofogliflozin), CVD outcomes trials (EMPAREG-OUTCOME, CANVAS and DECLARE-TIMI 58) and real-world evidence studies (CVD-REAL, EASEL, CVD-REAL 2 and OBSERVE-4D). A series of clinical recommendations on the use of SGLT-2 inhibitors in Asian patients with T2DM was deliberated among experts with multiple rounds of review and voting. Based on the available evidence, we conclude that SGLT-2 inhibitors represent an evidence-based therapeutic option for the primary prevention of heart failure hospitalization and secondary prevention of CVD in patients with T2DM, and should be considered early on in the treatment algorithm for patients with multiple risk factors, or those with established CVD.
Identifiants
pubmed: 31264765
doi: 10.1111/dom.13819
pmc: PMC6852284
doi:
Substances chimiques
Lipids
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2354-2367Informations de copyright
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Med Clin (Barc). 2008 May 10;130(17):641-4
pubmed: 18501125
Diabetes Obes Metab. 2016 Dec;18(12):1207-1216
pubmed: 27436788
Can J Diabetes. 2018 Apr;42 Suppl 1:S162-S169
pubmed: 29650091
Circulation. 2017 Oct 17;136(16):1548-1559
pubmed: 29038209
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
Diabetes Care. 2019 Jan;42(Suppl 1):S173-S181
pubmed: 30559241
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
Diabetes Obes Metab. 2017 Oct;19(10):1397-1407
pubmed: 28371205
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Diabetes Obes Metab. 2015 Dec;17(12):1180-93
pubmed: 26343814
Cardiovasc Diabetol. 2017 Mar 3;16(1):32
pubmed: 28253918
Int J Obes Relat Metab Disord. 2003 Jul;27(7):784-9
pubmed: 12821962
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
Lancet Diabetes Endocrinol. 2014 Dec;2(12):935-43
pubmed: 25081582
Am J Cardiol. 2007 Jun 18;99(12A):21i-33i
pubmed: 17599422
Diabetes Obes Metab. 2015 Jan;17(1):23-31
pubmed: 25175734
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetes Care. 2015 Mar;38(3):420-8
pubmed: 25271206
J Diabetes Investig. 2016 May;7(3):366-73
pubmed: 27330723
Can J Diabetes. 2018 Apr;42 Suppl 1:S196-S200
pubmed: 29650096
Diab Vasc Dis Res. 2015 Mar;12(2):90-100
pubmed: 25589482
Cardiovasc Diabetol. 2017 Jan 13;16(1):8
pubmed: 28086872
Diabetes Care. 2016 Jul;39(7):1108-14
pubmed: 27289126
Lancet. 2015 May 23;385(9982):2067-76
pubmed: 25765696
Cardiovasc Diabetol. 2016 Jun 18;15:89
pubmed: 27316668
Circulation. 1996 May 15;93(10):1809-17
pubmed: 8635260
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Circulation. 2017 Jul 18;136(3):249-259
pubmed: 28522450
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Diabetes Care. 2013 Jun;36(6):1789-96
pubmed: 23704681
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639
pubmed: 29540325
Circ J. 2017 Jan 25;81(2):227-234
pubmed: 28025462
Heart Fail Rev. 2015 May;20(3):291-303
pubmed: 25716909
Cardiovasc Diabetol. 2017 Jul 6;16(1):84
pubmed: 28683796
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Expert Opin Pharmacother. 2014 Aug;15(11):1501-15
pubmed: 25010793
Lancet Diabetes Endocrinol. 2016 Feb;4(2):115-24
pubmed: 26704379
J Diabetes Investig. 2015 Jul;6(4):443-53
pubmed: 26221523
J Formos Med Assoc. 2012 Nov;111(11):625-36
pubmed: 23217598
Global Health. 2013 Mar 14;9:11
pubmed: 23497447
Diabetes. 2002 May;51(5):1543-7
pubmed: 11978654
J Med Econ. 2017 May;20(5):549-553
pubmed: 28286996
BMJ. 2006 Jan 14;332(7533):73-8
pubmed: 16371403
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Can J Diabetes. 2018 Apr;42 Suppl 1:S88-S103
pubmed: 29650116
Diabetes Metab Res Rev. 2016 Jul;32(5):442-58
pubmed: 27464265
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Diabetes Obes Metab. 2015 Mar;17(3):304-8
pubmed: 24919820
Clin Ther. 2014 Jan 1;36(1):84-100.e9
pubmed: 24378206
BMJ Open. 2018 Jul 25;8(7):e021655
pubmed: 30049696
Diabetes Ther. 2014 Dec;5(2):415-33
pubmed: 25341477
N Engl J Med. 2003 Jan 30;348(5):383-93
pubmed: 12556541
Diabetes Care. 2008 May;31(5):893-8
pubmed: 18310309
Endocr J. 2015;62(7):593-603
pubmed: 25971406
JACC Heart Fail. 2016 Dec;4(12):911-919
pubmed: 27908389
Obesity (Silver Spring). 2012 Mar;20(3):525-32
pubmed: 21660082
Atherosclerosis. 2015 Sep;242(1):199-204
pubmed: 26204496
Diabetes Obes Metab. 2018 Nov;20(11):2585-2597
pubmed: 29938883
J Clin Endocrinol Metab. 2003 May;88(5):2300-8
pubmed: 12727989
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
PLoS Med. 2010 Feb 23;7(2):e1000236
pubmed: 20186272
Cardiovasc Diabetol. 2014 Mar 28;13:65
pubmed: 24678906
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Eur Heart J. 2016 Nov 07;37(42):3192-3200
pubmed: 27153861
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Diabetes Care. 2014;37(3):796-804
pubmed: 24130359
Diabetes Obes Metab. 2019 Nov;21(11):2354-2367
pubmed: 31264765
PLoS One. 2018 Nov 21;13(11):e0205745
pubmed: 30462648
J Diabetes. 2018 Jul;10(7):589-599
pubmed: 29215189
Diabetes Care. 2018 Feb;41(2):356-363
pubmed: 29203583
Circulation. 2002 Sep 3;106(10):1211-8
pubmed: 12208795
Blood Press. 2011 Dec;20(6):348-54
pubmed: 21675827
N Engl J Med. 2013 Apr 25;368(17):1613-24
pubmed: 23614587
Cardiovasc Diabetol. 2014 Jan 29;13:28
pubmed: 24475922
Adv Ther. 2015 Apr;32(4):306-18
pubmed: 25845768
Obes Rev. 2008 Mar;9 Suppl 1:53-61
pubmed: 18307700
J Diabetes Investig. 2017 Jul;8(4):510-517
pubmed: 28106956
Diabetes Obes Metab. 2015 Jul;17(7):665-74
pubmed: 25772548
JAMA. 2009 May 27;301(20):2129-40
pubmed: 19470990
Circulation. 2018 Apr 3;137(14):1450-1459
pubmed: 29133607
J Clin Endocrinol Metab. 2005 Mar;90(3):1483-8
pubmed: 15598684
J Am Coll Cardiol. 2013 Apr 2;61(13):1388-95
pubmed: 23433560
Diabetologia. 2015 Mar;58(3):429-42
pubmed: 25583541
Br J Nutr. 2008 Apr;99(4):840-5
pubmed: 17903341
J Am Heart Assoc. 2015 Nov 13;4(11):
pubmed: 26567372
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Eur Heart J. 2013 Oct;34(39):3035-87
pubmed: 23996285
PLoS One. 2018 Dec 21;13(12):e0208731
pubmed: 30576328
N Engl J Med. 2009 Jan 8;360(2):129-39
pubmed: 19092145
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
Circ J. 2013;77(9):2209-17
pubmed: 23955345
Diabetes Obes Metab. 2015 Oct;17(10):984-93
pubmed: 26179482
Am Heart J. 1994 Mar;127(3):674-82
pubmed: 8122618
Circulation. 2018 Jan 23;137(4):323-334
pubmed: 29133604
Diabetes Obes Metab. 2013 Sep;15(9):853-62
pubmed: 23668478
Drugs R D. 2016 Sep;16(3):255-261
pubmed: 27333994
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
Obes Rev. 2002 Aug;3(3):141-6
pubmed: 12164465
J Clin Endocrinol Metab. 2004 Jun;89(6):2750-5
pubmed: 15181053
Diabetes Metab. 2019 Jun;45(3):213-223
pubmed: 30708071
Circ J. 2016 Oct 25;80(11):2277-2281
pubmed: 27599528
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
Curr Med Res Opin. 2018 Jun;34(6):981-994
pubmed: 29448833
J Formos Med Assoc. 2020 Feb;119(2):577-586
pubmed: 30952480
Can J Diabetes. 2018 Apr;42 Suppl 1:S201-S209
pubmed: 29650098
Diabetes Ther. 2017 Aug;8(4):851-861
pubmed: 28616806
J Clin Med Res. 2016 Dec;8(12):844-847
pubmed: 27829948
Lancet Diabetes Endocrinol. 2016 Jan;4(1):2-3
pubmed: 26577717
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
Diabetes Obes Metab. 2014 May;16(5):457-66
pubmed: 24320621
Diabetes Res Clin Pract. 2011 Jun;92(3):312-21
pubmed: 21605924
J Nutr. 2002 Sep;132(9):2574-9
pubmed: 12221211
Endocr Pract. 2016 Jun;22(6):753-62
pubmed: 27082665